Partial agonist of Liver X Receptor (LXR; IC50 value 179 nM and 24 nM for LXRα- and LXRβ-binding, respectively. EC50 values 6.66 μM and 3.67 μM for Huh-7 human hepatoma cell based Gal4 LXRα and LXRβ transactivation essays respectively). Despite its partial agonism in transactivation essays, LXR 623 exhibits full agonism in THP-1 cells with respect to increasing ABCA1 gene expression and on cholesterol efflux in THP-1 foam cells. In vivo, LXR 623 lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse.